Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review

Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review

For a long time, cisplatin-based chemotherapy had been viewed as first-line chemotherapy for advanced and metastatic urothelial carcinoma (UC). However, many patients with UC had been classified as cisplatin-ineligible who can only receive alternative chemotherapy with poor treatment response, and t...

Full description

Bibliographic Details
Main Authors:	Huang-Yu Yang, Chao-Yi Wu, Jia-Jin Chen, Tao-Han Lee
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	International Journal of Molecular Sciences
Subjects:	urothelial carcinoma immune checkpoint inhibitors immunotherapy tumor microenvironment metabolic pathway
Online Access:	https://www.mdpi.com/1422-0067/21/23/8993

Similar Items

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma
by: Chaozheng Zhou, et al.
Published: (2021-06-01)

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
by: Wenqin Feng, et al.
Published: (2022-05-01)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
by: Chiang RS, et al.
Published: (2022-10-01)

Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
by: Guangdi Chu, et al.
Published: (2021-12-01)

Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile
by: Mou Peng, et al.
Published: (2022-08-01)

A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder
by: Huan Feng, et al.
Published: (2023-08-01)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
by: Tassinari E, et al.
Published: (2022-06-01)

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
by: Yoshiharu Okuyama, et al.
Published: (2022-03-01)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-02-01)

The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response
by: Junru Chen, et al.
Published: (2023-12-01)

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)

Mass cytometry reveals immune atlas of urothelial carcinoma
by: Qing Zhang, et al.
Published: (2022-06-01)

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma
by: Yueming Zhang, et al.
Published: (2021-08-01)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
by: Dietrich B, et al.
Published: (2018-01-01)

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: LYU Zhengqin, et al.
Published: (2024-03-01)

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
by: Veronica Mollica, et al.
Published: (2020-06-01)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
by: Jonathan Thouvenin, et al.
Published: (2021-08-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma
by: Wan Zhengqiang, et al.
Published: (2023-08-01)

Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation
by: Ying Dong, et al.
Published: (2023-05-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
by: Alexander Chehrazi-Raffle, et al.
Published: (2021-02-01)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
by: Ning Zan, et al.
Published: (2022-02-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
by: Pengju Li, et al.
Published: (2021-03-01)

Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective
by: Huang-Yu Yang, et al.
Published: (2020-06-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
by: Rola El Sayed, et al.
Published: (2021-02-01)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
by: Shibin Zhu, et al.
Published: (2022-10-01)

Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
by: Wai-Nga Chan, et al.
Published: (2022-09-01)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
by: Chaojie Xu, et al.
Published: (2022-03-01)

Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
by: Pratibha Pandey, et al.
Published: (2023-01-01)

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
by: Hsiao-Ling Chen, et al.
Published: (2021-03-01)

Understanding the Tumor Immune Microenvironment in Renal Cell Carcinoma
by: Daniel D. Shapiro, et al.
Published: (2023-04-01)